Iterum Therapeutics Competitors

Iterum Therapeutics (NASDAQ:ITRM) and Humanigen (NASDAQ:HGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Iterum Therapeutics and Humanigen's gross revenue, earnings per share and valuation.

Humanigen has lower revenue, but higher earnings than Iterum Therapeutics.

Profitability

This table compares Iterum Therapeutics and Humanigen's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Iterum Therapeutics and Humanigen, as reported by MarketBeat.

Iterum Therapeutics presently has a consensus target price of $3.25, indicating a potential upside of 146.21%. Humanigen has a consensus target price of $29.50, indicating a potential upside of 71.01%. Given Iterum Therapeutics' higher possible upside, equities research analysts plainly believe Iterum Therapeutics is more favorable than Humanigen.

Institutional and Insider Ownership

10.1% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Humanigen shares are owned by institutional investors. 22.1% of Iterum Therapeutics shares are owned by insiders. Comparatively, 37.5% of Humanigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Humanigen has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500.

Summary

Humanigen beats Iterum Therapeutics on 6 of the 10 factors compared between the two stocks.

Radius Health (NASDAQ:RDUS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Earnings & Valuation

This table compares Radius Health and Iterum Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Iterum Therapeutics has lower revenue, but higher earnings than Radius Health. Radius Health is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Radius Health and Iterum Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Radius Health and Iterum Therapeutics, as provided by MarketBeat.com.

Radius Health presently has a consensus price target of $24.60, indicating a potential upside of 26.22%. Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 146.21%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than Radius Health.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. 2.9% of Radius Health shares are held by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Radius Health has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.

Summary

Iterum Therapeutics beats Radius Health on 9 of the 13 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

90.2% of Prothena shares are held by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are held by institutional investors. 30.4% of Prothena shares are held by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Prothena and Iterum Therapeutics' revenue, earnings per share (EPS) and valuation.

Prothena has higher revenue and earnings than Iterum Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Iterum Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Prothena has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Prothena and Iterum Therapeutics, as provided by MarketBeat.

Prothena currently has a consensus price target of $29.4286, indicating a potential upside of 29.19%. Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 146.21%. Given Iterum Therapeutics' higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Prothena.

Summary

Prothena beats Iterum Therapeutics on 9 of the 14 factors compared between the two stocks.

Iterum Therapeutics (NASDAQ:ITRM) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Iterum Therapeutics and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Iterum Therapeutics currently has a consensus price target of $3.25, suggesting a potential upside of 146.21%. Vanda Pharmaceuticals has a consensus price target of $15.40, suggesting a potential downside of 5.23%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Iterum Therapeutics is more favorable than Vanda Pharmaceuticals.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 97.6% of Vanda Pharmaceuticals shares are held by institutional investors. 22.1% of Iterum Therapeutics shares are held by company insiders. Comparatively, 5.9% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Iterum Therapeutics and Vanda Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Vanda Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and Vanda Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vanda Pharmaceuticals beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks.

Iterum Therapeutics (NASDAQ:ITRM) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Iterum Therapeutics and BioXcel Therapeutics, as provided by MarketBeat.com.

Iterum Therapeutics currently has a consensus price target of $3.25, suggesting a potential upside of 146.21%. BioXcel Therapeutics has a consensus price target of $101.8182, suggesting a potential upside of 183.85%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Iterum Therapeutics.

Insider & Institutional Ownership

10.1% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 22.1% of Iterum Therapeutics shares are held by company insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Iterum Therapeutics and BioXcel Therapeutics' revenue, earnings per share (EPS) and valuation.

BioXcel Therapeutics has lower revenue, but higher earnings than Iterum Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and BioXcel Therapeutics' net margins, return on equity and return on assets.

Summary

BioXcel Therapeutics beats Iterum Therapeutics on 7 of the 12 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Merus and Iterum Therapeutics, as reported by MarketBeat.

Merus currently has a consensus target price of $27.80, suggesting a potential upside of 20.56%. Iterum Therapeutics has a consensus target price of $3.25, suggesting a potential upside of 146.21%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Merus.

Earnings and Valuation

This table compares Merus and Iterum Therapeutics' top-line revenue, earnings per share and valuation.

Merus has higher revenue and earnings than Iterum Therapeutics. Merus is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merus and Iterum Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

62.6% of Merus shares are owned by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are owned by institutional investors. 7.4% of Merus shares are owned by insiders. Comparatively, 22.1% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Merus has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.